Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit? - Kuemmel, S.; Jackisch, C.; Mueller, V.; Schneeweiss, A.; Klawitter, S.; Lux, Michael P. (2017)
EVALuna2:36166